Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Electra Therapeutics, Inc. (ETRA).
- 10 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 23 Sep 2026, 17:29.
ORBIMED ADVISORS LLC - 21 Sep 2026 Form 4 Insider Report for Electra Therapeutics, Inc. (ETRA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ETRA
- Reported as of
- 21 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Sep 2026, 17:29:42 UTC
- Prior SEC filing
- 18 Sep 2026
- Next SEC filing
- 24 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Electra Therapeutics, Inc. (ETRA) on 23 Sep 2026.
Change
- Previous filing in this sequence was filed on 18 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001055951
Primary reporting owner
ORBIMED ADVISORS LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Signature date
- 23 Sep 2026
CIK 0001760648
OrbiMed Capital GP VII LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VII LLC
- Signature date
- 23 Sep 2026
CIK 0001808744
OrbiMed Genesis GP LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
- Signature date
- 23 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,002,310
- Change %
- Price
- Shares after
- 2,002,310
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,002,310
- Change %
- Price
- Shares after
- 2,002,310
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,002,310
- Change %
- Price
- Shares after
- 2,002,310
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,087,934
- Change %
- +54%
- Price
- Shares after
- 3,090,244
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,087,934
- Change %
- +54%
- Price
- Shares after
- 3,090,244
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,087,934
- Change %
- +54%
- Price
- Shares after
- 3,090,244
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,703,314
- Change %
- +55%
- Price
- Shares after
- 4,793,558
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,703,314
- Change %
- +55%
- Price
- Shares after
- 4,793,558
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,703,314
- Change %
- +55%
- Price
- Shares after
- 4,793,558
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F5
ETRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +333,333
- Change %
- +7%
- Price
- $15.00*
- Shares after
- 5,126,891
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F3, F5
ETRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +333,333
- Change %
- +7%
- Price
- $15.00*
- Shares after
- 5,126,891
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F3, F5
ETRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +333,333
- Change %
- +7%
- Price
- $15.00*
- Shares after
- 5,126,891
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F3, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +758,279
- Change %
- Price
- Shares after
- 758,279
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +758,279
- Change %
- Price
- Shares after
- 758,279
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
ETRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +758,279
- Change %
- Price
- Shares after
- 758,279
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
ETRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +1,000,000
- Change %
- +132%
- Price
- $15.00*
- Shares after
- 1,758,279
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F4, F5
ETRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +1,000,000
- Change %
- +132%
- Price
- $15.00*
- Shares after
- 1,758,279
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F4, F5
ETRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +1,000,000
- Change %
- +132%
- Price
- $15.00*
- Shares after
- 1,758,279
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ETRA
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,002,310
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,002,310
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,002,310
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,002,310
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,002,310
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,002,310
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,087,934
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,087,934
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,087,934
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,087,934
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,087,934
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,087,934
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,703,314
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,703,314
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,703,314
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,703,314
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,703,314
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,703,314
- Exercise price
- Footnotes
- F1, F3, F5
ETRA
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -758,279
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 758,279
- Exercise price
- Footnotes
- F1, F4, F5
ETRA
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -758,279
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 758,279
- Exercise price
- Footnotes
- F1, F4, F5
ETRA
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -758,279
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 758,279
- Exercise price
- Footnotes
- F1, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering on September 21, 2026 without payment of further consideration. The Preferred Stock has no expiration date.
Footnote F2
Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Footnote F3
These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
Footnote F4
These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
Footnote F5
This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.